These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38426198)

  • 21. The role of irisin in metabolic flexibility: Beyond adipose tissue browning.
    Shen S; Liao Q; Chen X; Peng C; Lin L
    Drug Discov Today; 2022 Aug; 27(8):2261-2267. PubMed ID: 35364272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement.
    Donini LM; Busetto L; Bischoff SC; Cederholm T; Ballesteros-Pomar MD; Batsis JA; Bauer JM; Boirie Y; Cruz-Jentoft AJ; Dicker D; Frara S; Frühbeck G; Genton L; Gepner Y; Giustina A; Gonzalez MC; Han HS; Heymsfield SB; Higashiguchi T; Laviano A; Lenzi A; Nyulasi I; Parrinello E; Poggiogalle E; Prado CM; Salvador J; Rolland Y; Santini F; Serlie MJ; Shi H; Sieber CC; Siervo M; Vettor R; Villareal DT; Volkert D; Yu J; Zamboni M; Barazzoni R
    Obes Facts; 2022; 15(3):321-335. PubMed ID: 35196654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myostatin: Basic biology to clinical application.
    Esposito P; Picciotto D; Battaglia Y; Costigliolo F; Viazzi F; Verzola D
    Adv Clin Chem; 2022; 106():181-234. PubMed ID: 35152972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sarcopenia in Hepatocellular Carcinoma: Pathogenesis and Management.
    Gallo P; Silletta M; De Vincentis A; Lo Prinzi F; Terracciani F; Di Fazio G; Flagiello V; Vespasiani Gentilucci U; Antonelli Incalzi R; Picardi A
    Chemotherapy; 2022; 67(3):152-163. PubMed ID: 34974449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study.
    Roh E; Hwang SY; Yoo HJ; Baik SH; Lee JH; Son SJ; Kim HJ; Park YS; Lee SG; Cho BL; Jang HC; Kim BJ; Kim M; Won CW; Choi KM
    Hepatol Int; 2022 Jun; 16(3):545-554. PubMed ID: 34780030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effects of 12-Week Beta-Hydroxy-Beta-Methylbutyrate Supplementation in Patients with Liver Cirrhosis: Results from a Randomized Controlled Single-Blind Pilot Study.
    Lattanzi B; Bruni A; Di Cola S; Molfino A; De Santis A; Muscaritoli M; Merli M
    Nutrients; 2021 Jul; 13(7):. PubMed ID: 34371806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis.
    Habig G; Smaltz C; Halegoua-DeMarzio D
    Metabolites; 2021 Apr; 11(4):. PubMed ID: 33920751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-alcoholic fatty liver disease.
    Powell EE; Wong VW; Rinella M
    Lancet; 2021 Jun; 397(10290):2212-2224. PubMed ID: 33894145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sarcopenia in nonalcoholic fatty liver disease and all-cause and cause-specific mortality in the United States.
    Kim D; Wijarnpreecha K; Sandhu KK; Cholankeril G; Ahmed A
    Liver Int; 2021 Aug; 41(8):1832-1840. PubMed ID: 33641244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exercise physiology in cirrhosis and the potential benefits of exercise interventions: A review.
    West J; Gow PJ; Testro A; Chapman B; Sinclair M
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2687-2705. PubMed ID: 33638197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sarcopenic Obesity in Non-Alcoholic Fatty Liver Disease-The Union of Two Culprits.
    Emhmed Ali S; Nguyen MH
    Life (Basel); 2021 Feb; 11(2):. PubMed ID: 33557355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis.
    Chakravarthy MV; Siddiqui MS; Forsgren MF; Sanyal AJ
    Front Endocrinol (Lausanne); 2020; 11():592373. PubMed ID: 33424768
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Gao F; Zheng KI; Zhu PW; Li YY; Ma HL; Li G; Tang LJ; Rios RS; Liu WY; Pan XY; Targher G; Byrne CD; Chen YP; Zheng MH
    Br J Nutr; 2021 Sep; 126(6):813-824. PubMed ID: 33198849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH.
    Hegazy MA; Mogawer SM; Alnaggar ARLR; Ghoniem OA; Abdel Samie RM
    Diabetes Metab Syndr Obes; 2020; 13():3861-3872. PubMed ID: 33116732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irisin in Liver Cirrhosis.
    Kukla M; Skladany L; Menżyk T; Derra A; Stygar D; Skonieczna M; Hudy D; Nabrdalik K; Gumprecht J; Marlicz W; Koulaouzidis A; Koller T
    J Clin Med; 2020 Sep; 9(10):. PubMed ID: 33003490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between serum irisin concentrations and sarcopenia in patients with liver cirrhosis: a cross-sectional study.
    Zhao M; Zhou X; Yuan C; Li R; Ma Y; Tang X
    Sci Rep; 2020 Sep; 10(1):16093. PubMed ID: 32999391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease.
    Golabi P; Gerber L; Paik JM; Deshpande R; de Avila L; Younossi ZM
    JHEP Rep; 2020 Dec; 2(6):100171. PubMed ID: 32964202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Long-Term Moderate Physical Exercise on Irisin between Normal Weight and Obese Men.
    Rashid FA; Abbas HJ; Naser NA; Addai Ali H
    ScientificWorldJournal; 2020; 2020():1897027. PubMed ID: 32952453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin: too much of a good thing is bad.
    Kolb H; Kempf K; Röhling M; Martin S
    BMC Med; 2020 Aug; 18(1):224. PubMed ID: 32819363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exercise and physical activity in cirrhosis: opportunities or perils.
    Bellar A; Welch N; Dasarathy S
    J Appl Physiol (1985); 2020 Jun; 128(6):1547-1567. PubMed ID: 32240017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.